Thiopurine metabolite ratios for monitoring therapy in pediatric crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 59, Issue 4, 2014, Pages 511-515

  Kopylov, U ^a   Amre, D ^b   Theoret, Y ^b   Deslandres, C ^b   Seidman, E G ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

6 Methylmecaptopurine; 6 Thioguanine; Azathioprine; Crohn disease; Drug monitoring; Thiopurines

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 METHYLMECAPTOPURINE; AZATHIOPRINE; DRUG METABOLITE; MERCAPTOPURINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG; 6-METHYLTHIOPURINE; 6-THIOGUANYLIC ACID; GUANINE NUCLEOTIDE; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE; NUCLEOTIDE;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL EVALUATION; CROHN DISEASE; CROSS-SECTIONAL STUDY; DRUG MONITORING; DRUG TREATMENT FAILURE; ERYTHROCYTE COUNT; FEMALE; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RECURRENCE RISK; RELAPSE; REMISSION; THERAPY; TOXIC HEPATITIS; ADOLESCENT; ANALOGS AND DERIVATIVES; DRUG-INDUCED LIVER INJURY; METABOLISM; RISK; TREATMENT FAILURE;

6-MERCAPTOPURINE; ADOLESCENT; AZATHIOPRINE; CHILD; CROHN DISEASE; DRUG-INDUCED LIVER INJURY; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLTRANSFERASES; ODDS RATIO; THIONUCLEOTIDES; TREATMENT FAILURE;

EID: 84917742200     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000455     Document Type: Article

References (32)

1. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; 1: CD000067.
2. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010; 6: CD000545.
3. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-94.
4. Chouchana L, Narjoz C, Beaune P, et al. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 15-36.
5. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-50.
6. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6.
7. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
8. Konidari A, Anagnostopoulos A, Bonnett LJ, et al. Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol 2014; 78: 467-76.
9. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62.
10. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003; 3 (suppl 1): S30-8.
11. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
12. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-43.
13. Leung Y, Sparrow MP, Schwartz M, et al. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis 2009; 3: 162-7.
14. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5: 209-14.
15. Vilela EG, Torres HO, Martins FP, et al. Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. World J Gastroenterol 2012; 18: 872-81.
16. Kamperidis N, Goodhand JR, Chowdhury FA, et al. Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2012; 54: 685-9.
17. Armstrong L, Sharif JA, Galloway P, et al. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine. Aliment Pharmacol Ther 2011; 34: 1106-14.
18. Gupta P, Gokhale R, Kirschner BS. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 450-4.
19. Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010; 16: 1541-9.
20. LeLeiko NS, Lobato D, Hagin S, et al. 6-Thioguanine levels in pediatric IBD patients: adherence is more important than dose. Inflamm Bowel Dis 2013; 19: 2652-8.
21. van Egmond R, Chin P, Zhang M, et al. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther 2012; 35: 1181-9.
22. Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf 2008; 7: 607-16.
23. Gilissen LP, Derijks LJ, Bos LP, et al. Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin Drug Investig 2004; 24: 479-86.
24. Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 734-41.
25. Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011; 17: 4166-73.
26. Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1678-82.
27. Seinen ML, van Asseldonk DP, de Boer NK, et al. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. J Crohns Colitis 2013; 7: 812-9.
28. Smith MA, Blaker P, Marinaki AM, et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 2012; 6: 905-12.
29. Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 363-9.
30. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-Aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006; 12: 251-7.
31. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br JClinPharmacol 1995; 39: 456-9.
32. Shih DQ, Nguyen M, Zheng L, et al. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 2012; 36: 449-58.